At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 11, 2026 at 07:00 ET
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival across all HER2 expression levels, with a manageable safety profile. The data support the drug's potential in a high-unmet-need population, including those with prior checkpoint inhibitor exposure.
- Phase 2 cohort of 145 patients with advanced HER2-expressing endometrial cancer met primary endpoint of objective response rate (ORR).
- Confirmed ORR was 47.9% in centrally tested patients (n=96), with 49.3% in those previously treated with checkpoint inhibitors.
- Median progression-free survival was 8.1 months (95% CI: 5.5, 11.8) in centrally tested patients.
- Trastuzumab pamirtecan showed activity across all HER2 expression levels (IHC1+, IHC2+, IHC3+) and in real-world populations including those with visceral metastases.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access